We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+22.23%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$18.5B
AUM Growth
+$2.83B
Cap. Flow
+$342M
Cap. Flow %
1.85%
Top 10 Hldgs %
16.55%
Holding
2,427
New
891
Increased
366
Reduced
546
Closed
599

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$163M
2
CCL icon
Carnival Corporation Ltd
CCL
+$137M
3
RGEN icon
Repligen
RGEN
+$104M
4
BIIB icon
Biogen
BIIB
+$104M
5
ZTS icon
Zoetis
ZTS
+$91.9M

Sector Composition

Rank Sector Weight
1 Healthcare 28.24%
2 Consumer Discretionary 12.89%
3 Financials 10.77%
4 Technology 9.62%
5 Industrials 4.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WTW icon
76
Willis Towers Watson
WTW
$27.9B
$49.3M 0.27%
234,033
-114,494
-33% -$23.6M
VAR
77
DELISTED
Varian Medical Systems, Inc.
VAR
$49.1M 0.27%
280,836
+178,643
+175% +$31M
IYR icon
78
CALL
iShares US Real Estate ETF
IYR
$4.59B
$48.7M 0.26%
+569,000
New +$47.4M
RVTY icon
79
Revvity
RVTY
$12.3B
$47.4M 0.26%
330,394
-124,275
-27% -$16.5M
VRTX icon
80
Vertex Pharmaceuticals
VRTX
$121B
$47.2M 0.26%
199,587
+158,119
+381% +$36.3M
IQV icon
81
IQVIA
IQV
$34.7B
$47M 0.25%
262,359
-39,143
-13% -$6.6M
BLFS icon
82
BioLife Solutions
BLFS
$1.46B
$46.3M 0.25%
+1,161,665
New +$39.6M
XLU icon
83
PUT
State Street Utilities Select Sector SPDR ETF
XLU
$24.1B
$45.9M 0.25%
1,463,000
+671,400
+85% +$21.2M
DISCK
84
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
$45.6M 0.25%
1,742,811
-149,704
-8% -$3.28M
ACAD icon
85
Acadia Pharmaceuticals
ACAD
$4.25B
$45.4M 0.25%
848,679
-285,133
-25% -$14.2M
ENB icon
86
Enbridge
ENB
$124B
$44.5M 0.24%
1,392,972
+525,072
+60% +$16M
PPD
87
DELISTED
PPD, Inc. Common Stock
PPD
$44.3M 0.24%
1,294,910
+399,418
+45% +$14M
SNAP icon
88
Snap
SNAP
$7.32B
$44.2M 0.24%
+882,693
New +$36.7M
NVTA
89
DELISTED
Invitae Corporation
NVTA
$43.8M 0.24%
+1,048,349
New +$50.1M
BNS icon
90
Scotiabank
BNS
$106B
$43.5M 0.24%
805,597
+636,209
+376% +$30.2M
XLNX
91
DELISTED
Xilinx Inc
XLNX
$43.3M 0.23%
305,657
+295,568
+2,930% +$38.4M
PCTY icon
92
Paylocity
PCTY
$6.71B
$42.9M 0.23%
+208,504
New +$40.1M
PRU icon
93
Prudential Financial
PRU
$41.7B
$42M 0.23%
538,052
+36,100
+7% +$2.61M
XYZ
94
Block Inc
XYZ
$45.9B
$41.8M 0.23%
+191,837
New +$37.4M
MXIM
95
DELISTED
Maxim Integrated Products
MXIM
$41.5M 0.22%
468,179
-277,807
-37% -$21.9M
EEM icon
96
PUT
iShares MSCI Emerging Markets ETF
EEM
$28B
$40.7M 0.22%
787,700
+384,600
+95% +$18.5M
HCAT icon
97
Health Catalyst
HCAT
$154M
$40.5M 0.22%
930,186
+70,456
+8% +$2.6M
MS icon
98
Morgan Stanley
MS
$337B
$40.4M 0.22%
589,226
-703,401
-54% -$40.4M
WPM icon
99
Wheaton Precious Metals
WPM
$50.6B
$40M 0.22%
959,112
+770,329
+408% +$34.4M
SCCO icon
100
Southern Copper
SCCO
$141B
$39.9M 0.22%
660,434
+432,057
+189% +$22.2M

Similar funds

Marshall Wace's Q4 2020 Portfolio in Review

As of Q4 2020, Marshall Wace held 2,427 positions worth $18.5B, up 18% from $15.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Marshall Wace's Q4 2020 filing shows 891 new, 366 increased, 546 reduced and 599 closed positions. Its largest new stake was Natera: 911,254 shares worth $90.7M. The largest sale was Alphabet (Google) Class A, an estimated $173M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Marshall Wace's largest Q4 2020 buy was Natera: 911,254 shares worth $90.7M.
  • Marshall Wace added most to Thermo Fisher Scientific in Q4 2020, an estimated $163M increase.
  • Marshall Wace's biggest Q4 2020 reduction was Alphabet (Google) Class A, cutting an estimated $173M.
  • Marshall Wace fully exited FedEx in Q4 2020, selling an estimated $69.6M.
  • Marshall Wace's ten largest holdings make up 17% of its $18.5B portfolio in Q4 2020.
  • Marshall Wace opened 891 new positions and closed 599 in Q4 2020.
  • Marshall Wace's portfolio value rose 18% quarter-over-quarter to $18.5B.

Based on Marshall Wace's 13F filing for Q4 2020, filed 16 Feb 2021.